Innovating Works

XENOPAT

Activa
CRYSTAL3: Commercial & Research Opportunity for Cysteinyl Leukotriene Signalling in Ocular & CNS Dysfunction, Cancer and Cardiovascular Disease UNIVERSITY COLLEGE DUBLIN NATIONAL UNIVERSITY OF IRELAND DUBLIN tramitó un H2020: Cysteinyl leukotrienes (CysLTs) are potent lipid mediators of inflammation. CysLT1 and 2 receptors are widely expressed e.g. lungs, colorectum, heart, brain & eye; and CysLT1 antagonists are prescribe...
2021-01-01 | Financiado
cONCReTE: DevelOpmeNt of Cancer RNA TherapEutics UNIVERSITA DEGLI STUDI DI NAPOLI FEDERICO II tramitó un H2020: Non-codingRNAs (ncRNAs) represent a large class of molecules that in concert regulate the expression of genes involved in the key pathways governing cancer development and progression. They represent...
2020-05-01 | Financiado
EPIPHARM: Development of a ncRNA DNA Methylation Kit for Treatment Guidance in Cancer of Unknown Primary FUNDACIO INSTITUT D?INVESTIGACIO BIOMEDICA DE BELLVITGE (IDIBELL) tramitó un FP7: The innovative idea behind the EPIPHARM (EPIgenetics of PHARMacogenetics) project is to develop a package demonstrating the feasibility of a high-throughput tool for epigenotyping Cancer of Unknown Pr...
2017-02-01 | Financiado
3D NEONET: Drug Discovery and Delivery NEtwork for ONcology and Eye Therapeutics UNIVERSITY COLLEGE DUBLIN NATIONAL UNIVERSITY OF IRELAND DUBLIN tramitó un H2020: Severe ocular disorders are affecting the lives of more than 100Mill people world-wide and at least 25% of the population above 70 years of age, a growing demographic group in EU. More than 8 million...
2017-01-01 | Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.